This vaccine, officially named “Vaxzevria”, is more commonly known as “AstraZeneca.”
This vaccine uses adenovirus vaccine vector (recombinant), which contains modified common flu vaccine that cannot replicate in human body but can still initiate immune response to COVID-19.
AstraZeneca Vaccine have obtained an emergency user authorization:
This vaccine is injected into the upper arm, for 2 doses. The second dose is administered 12 weeks after the first dose.
Several contraindication for AstraZeneca Vaccine include:
|Pain/swelling/itch near the injection area, feeling tired, headache, muscle/joint pain, nausea, fever >38oC||Common|
|Redness/swelling near the injection area, diarrhea, vomiting||Less Common|
|Reduced appetite, dizziness, sleepiness, sweating, swollen lymph gland, rash||Rare|
|Blood clot, capillary leak syndrome||Very Rare|
Trombosis with Thrombocytopenia Syndrome (TTS) is blood clotting with a low blood platelet count. This can occur in the vessels of the brain, abdomen, and lungs. TTS can cause serious long term disability and death.
1 in 100.000 people; 1 in 5 of these people may die
Risk period: 4 – 20 days after vaccination (usually after the first dose)
Symptoms needing medical attention: